Please enable JavaScript to continue using this application.

Compare $RLAY vs $TNGX | Chartloom

Compare

$RLAY vs $TNGX

Relay Therapeutics Inc · Tango Therapeutics Inc

RLAY

Relay Therapeutics Inc

TNGX

Tango Therapeutics Inc

Compare $RLAY vs $TNGX

Comparing Relay Therapeutics Inc and Tango Therapeutics Inc

RLAYRelay Therapeutics Inc

TNGXTango Therapeutics Inc

RLAYRelay Therapeutics Inc

Market cap

$3.85B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

610.65x

Rev growth (TTM)

23.9%

YTD performance

118.6%

52W performance

192.6%

FCF yield

-5.5%

TNGXTango Therapeutics Inc

Market cap

$3.87B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

121.5%

YTD performance

166.6%

52W performance

244.6%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RLAY

TNGX

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

TNGX

Tango Therapeutics Inc

Market Cap

RLAY$3.85B

TNGX$3.87B

Enterprise Value

RLAY$3.73B

TNGX$3.52B

Price

RLAY$17.88

TNGX$23.81

P/E Ratio

RLAYN/A

TNGXN/A

P/S Ratio

RLAY372.39x

TNGX71.83x

EV/Sales

RLAY360.68x

TNGX65.41x

EV/EBITDA

RLAY0.00x

TNGX0.00x

P/B Ratio

RLAY4.67x

TNGX3.82x

P/FCF Ratio

RLAYN/A

TNGXN/A

EV/FCF

RLAY-17.59x

TNGX-24.40x

PEG Ratio

RLAYN/A

TNGXN/A

Forward P/E (NTM)

RLAYN/A

TNGXN/A

Forward P/S (NTM)

RLAY610.65x

TNGXN/A

Revenue (TTM)

RLAY$10M

TNGX$54M

Revenue Growth (YoY)

RLAY23.9%

TNGX121.5%

Forward Rev Growth

RLAY64.1%

TNGX732.8%

Gross Margin (TTM)

RLAY0.0%

TNGX0.0%

Operating Margin (TTM)

RLAY0.0%

TNGX0.0%

EBITDA Margin (TTM)

RLAY-2978.0%

TNGX-249.8%

Net Margin (TTM)

RLAY-2763.6%

TNGX-229.9%

FCF Margin (TTM)

RLAY-2050.3%

TNGX-268.1%

Net Income (TTM)

RLAY$-286M

TNGX$-124M

FCF (TTM)

RLAY$-212M

TNGX$-144M

EPS (TTM)

RLAY-$1.41

TNGX-$0.83

ROE (TTM)

RLAY-4227.0%

TNGX-2574.0%

ROA (TTM)

RLAY-3867.0%

TNGX-2336.0%

ROIC (TTM)

RLAY-4227.0%

TNGX-2574.0%

Cash

RLAY$121M

TNGX$346M

Debt

RLAY$0

TNGX$0

Net Cash/Debt

RLAY$121M

TNGX$346M

Current Ratio (TTM)

RLAY18.27x

TNGX50.82x

Quick Ratio (TTM)

RLAY18.10x

TNGX49.95x

Debt/Equity (TTM)

RLAY0.00x

TNGX0.00x

Debt/Assets (TTM)

RLAY0.0%

TNGX0.0%

Interest Coverage (TTM)

RLAYN/A

TNGXN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

TNGX0.00x

Beta

RLAY1.71

TNGX1.18

52W Performance

RLAY192.6%

TNGX244.6%

YTD Performance

RLAY118.6%

TNGX166.6%

% from 52W High

RLAY-15.9%

TNGX-30.8%

% from 52W Low

RLAY205.6%

TNGX255.9%

Asset Turnover (TTM)

RLAY0.01x

TNGX0.26x

FCF Yield (TTM)

RLAY-5.5%

TNGX-3.7%

Earnings Yield (TTM)

RLAY-7.4%

TNGX-3.2%

Dividend Yield (TTM)

RLAYN/A

TNGXN/A

Rule of 40

RLAY-2,026.4

TNGX-146.6

EV/GP/RG

RLAYN/A

TNGXN/A

Ticker research

View RLAY research View TNGX research

Metric	RLAY Relay Therapeutics Inc	TNGX Tango Therapeutics Inc
Market & Valuation
Market Cap	$3.85B	$3.87B
Enterprise Value	$3.73B	$3.52B
Price	$17.88	$23.81
P/E Ratio	N/A	N/A
P/S Ratio	372.39x	71.83x
EV/Sales	360.68x	65.41x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.67x	3.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.59x	-24.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	610.65x	N/A
Revenue & Growth
Revenue (TTM)	$10M	$54M
Revenue Growth (YoY)	23.9%	121.5%
Forward Rev Growth	64.1%	732.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2978.0%	-249.8%
Net Margin (TTM)	-2763.6%	-229.9%
FCF Margin (TTM)	-2050.3%	-268.1%
Net Income (TTM)	$-286M	$-124M
FCF (TTM)	$-212M	$-144M
EPS (TTM)	-$1.41	-$0.83
ROE (TTM)	-4227.0%	-2574.0%
ROA (TTM)	-3867.0%	-2336.0%
ROIC (TTM)	-4227.0%	-2574.0%
Financial Health
Cash	$121M	$346M
Debt	$0	$0
Net Cash/Debt	$121M	$346M
Current Ratio (TTM)	18.27x	50.82x
Quick Ratio (TTM)	18.10x	49.95x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.18
52W Performance	192.6%	244.6%
YTD Performance	118.6%	166.6%
% from 52W High	-15.9%	-30.8%
% from 52W Low	205.6%	255.9%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.26x
FCF Yield (TTM)	-5.5%	-3.7%
Earnings Yield (TTM)	-7.4%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	-146.6
EV/GP/RG	N/A	N/A
Ticker research	View RLAY research	View TNGX research

Valuation

P/S Ratio

TNGX

71.83x

RLAY

372.39x

EV/FCF

TNGX

-24.40x

RLAY

-17.59x

Growth & revenue

Revenue Growth TTM

TNGX

121.5%

RLAY

23.9%

Forward Revenue Growth

TNGX

732.8%

RLAY

64.1%

Profitability & performance

Gross Margin

RLAY

0.0%

TNGX

0.0%

ROE

TNGX

-2574.0%

RLAY

-4227.0%

FCF Yield %

TNGX

-3.7%

RLAY

-5.5%

52-Week Performance

TNGX

244.6%

RLAY

192.6%

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

TNGX

Tango Therapeutics Inc

Market Cap

RLAY$3.85B

TNGX$3.87B

Enterprise Value

RLAY$3.73B

TNGX$3.52B

Price

RLAY$17.88

TNGX$23.81

P/E Ratio

RLAYN/A

TNGXN/A

P/S Ratio

RLAY372.39x

TNGX71.83x

EV/Sales

RLAY360.68x

TNGX65.41x

EV/EBITDA

RLAY0.00x

TNGX0.00x

P/B Ratio

RLAY4.67x

TNGX3.82x

P/FCF Ratio

RLAYN/A

TNGXN/A

EV/FCF

RLAY-17.59x

TNGX-24.40x

PEG Ratio

RLAYN/A

TNGXN/A

Forward P/E (NTM)

RLAYN/A

TNGXN/A

Forward P/S (NTM)

RLAY610.65x

TNGXN/A

Revenue (TTM)

RLAY$10M

TNGX$54M

Revenue Growth (YoY)

RLAY23.9%

TNGX121.5%

Forward Rev Growth

RLAY64.1%

TNGX732.8%

Gross Margin (TTM)

RLAY0.0%

TNGX0.0%

Operating Margin (TTM)

RLAY0.0%

TNGX0.0%

EBITDA Margin (TTM)

RLAY-2978.0%

TNGX-249.8%

Net Margin (TTM)

RLAY-2763.6%

TNGX-229.9%

FCF Margin (TTM)

RLAY-2050.3%

TNGX-268.1%

Net Income (TTM)

RLAY$-286M

TNGX$-124M

FCF (TTM)

RLAY$-212M

TNGX$-144M

EPS (TTM)

RLAY-$1.41

TNGX-$0.83

ROE (TTM)

RLAY-4227.0%

TNGX-2574.0%

ROA (TTM)

RLAY-3867.0%

TNGX-2336.0%

ROIC (TTM)

RLAY-4227.0%

TNGX-2574.0%

Cash

RLAY$121M

TNGX$346M

Debt

RLAY$0

TNGX$0

Net Cash/Debt

RLAY$121M

TNGX$346M

Current Ratio (TTM)

RLAY18.27x

TNGX50.82x

Quick Ratio (TTM)

RLAY18.10x

TNGX49.95x

Debt/Equity (TTM)

RLAY0.00x

TNGX0.00x

Debt/Assets (TTM)

RLAY0.0%

TNGX0.0%

Interest Coverage (TTM)

RLAYN/A

TNGXN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

TNGX0.00x

Beta

RLAY1.71

TNGX1.18

52W Performance

RLAY192.6%

TNGX244.6%

YTD Performance

RLAY118.6%

TNGX166.6%

% from 52W High

RLAY-15.9%

TNGX-30.8%

% from 52W Low

RLAY205.6%

TNGX255.9%

Asset Turnover (TTM)

RLAY0.01x

TNGX0.26x

FCF Yield (TTM)

RLAY-5.5%

TNGX-3.7%

Earnings Yield (TTM)

RLAY-7.4%

TNGX-3.2%

Dividend Yield (TTM)

RLAYN/A

TNGXN/A

Rule of 40

RLAY-2,026.4

TNGX-146.6

EV/GP/RG

RLAYN/A

TNGXN/A

Ticker research

View RLAY research View TNGX research

Metric	RLAY Relay Therapeutics Inc	TNGX Tango Therapeutics Inc
Market & Valuation
Market Cap	$3.85B	$3.87B
Enterprise Value	$3.73B	$3.52B
Price	$17.88	$23.81
P/E Ratio	N/A	N/A
P/S Ratio	372.39x	71.83x
EV/Sales	360.68x	65.41x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.67x	3.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.59x	-24.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	610.65x	N/A
Revenue & Growth
Revenue (TTM)	$10M	$54M
Revenue Growth (YoY)	23.9%	121.5%
Forward Rev Growth	64.1%	732.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2978.0%	-249.8%
Net Margin (TTM)	-2763.6%	-229.9%
FCF Margin (TTM)	-2050.3%	-268.1%
Net Income (TTM)	$-286M	$-124M
FCF (TTM)	$-212M	$-144M
EPS (TTM)	-$1.41	-$0.83
ROE (TTM)	-4227.0%	-2574.0%
ROA (TTM)	-3867.0%	-2336.0%
ROIC (TTM)	-4227.0%	-2574.0%
Financial Health
Cash	$121M	$346M
Debt	$0	$0
Net Cash/Debt	$121M	$346M
Current Ratio (TTM)	18.27x	50.82x
Quick Ratio (TTM)	18.10x	49.95x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.18
52W Performance	192.6%	244.6%
YTD Performance	118.6%	166.6%
% from 52W High	-15.9%	-30.8%
% from 52W Low	205.6%	255.9%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.26x
FCF Yield (TTM)	-5.5%	-3.7%
Earnings Yield (TTM)	-7.4%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	-146.6
EV/GP/RG	N/A	N/A
Ticker research	View RLAY research	View TNGX research